Neurofibromatosis 1 Clinical Trial
Official title:
Pilot Study of Medication Adherence in Children, Adolescents, and Adults With Neurofibromatosis Type 1 (NF1) on Clinical Treatment Trials
Verified date | April 2024 |
Source | National Institutes of Health Clinical Center (CC) |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Background: Neurofibromatosis type 1 (NF1) is a genetic disorder. It has a broad variety of effects on the body. Up to half of people with NF1 get plexiform neurofibromas (PNs). These are benign tumors. But they can have serious effects like pain and disfigurement. To treat PNs, a person may have to take medicine every day for a long period of time. Researchers think that it will be important for people to take the medicine regularly for it to work. They want to study how well people with NF1 follow their treatment plan for PNs. Objective: To study how often people with neurofibromatosis type 1 take medicine that has been prescribed to them for treating plexiform neurofibromas. Eligibility: People ages 3-59 already enrolled in an NF1 clinical trial Design: Participants will need access to the internet to do the study activities. Parents or caregivers will do some study activities for child participants. Participants will complete 5 questionnaires. They will take about 20 minutes total. The topics will be: Demographic data Recent life events How much pain interferes with daily life Ability to focus and pay attention to tasks Emotional distress or depression Participants will mark down every time they take a dose of the medicine in their clinical trial. They will use a form the researchers give them. The pill bottles they get in their trial will have a chip in the cap that will record when it is opened. Participants will keep a daily diary of their medicine. Their pills will be counted at clinical trial visits. Participants may have more short questionnaires. They may have interviews by phone or video.
Status | Completed |
Enrollment | 12 |
Est. completion date | March 20, 2023 |
Est. primary completion date | March 20, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 3 Years to 59 Years |
Eligibility | - INCLUSION CRITERIA: Inclusion Criteria for Patient - Patients must be between 3 and 59 years of age at the time of the baseline assessment. - Patients must be enrolled on a neurofibromatosis Type 1 (NF1) clinical trial for an oral medication directed at the treatment of plexiform neurofibroma(s) (enrollment on this study to occur ideally within 1st cycle) Patients must have regular access to a computer or electronic device (e.g., smartphone, tablet) with internet access. - Must have a parent or adult primary caregiver willing to participate in the study. - Ability of subject or Legally Authorized Representative (LAR) to understand and the willingness to sign a written informed consent document. - Subjects must be able to read and comprehend the English language. Inclusion Criteria for Parents or Caregivers - Must be a parent or primary caregiver of a child (or if applicable adult patient) of diagnosed with NF1 and enrolled on a clinical trial for oral medication. - Must have a child (or if applicable adult patient) willing to participate in the study - Must have regular access to a computer or electronic device (e.g., smartphone, tablet) with internet access. - Must be able to speak and understand English. - Ability of subject to understand and the willing to sign a written informed consent document. EXCLUSION CRITERIA: Exclusion Criteria for Patient - In the opinion of the principal investigator (PI) or an associate investigator (AI), the subject has significant cognitive or emotional difficulties that would prevent them from being able to understand and/or participate fully in the study or complete the measures. Though these patients might be receiving assistance in taking medication from a caregiver, it is likely that their medication taking routine would be significantly different from the general population of patients with NF1. - Patients receiving the study drug in liquid form, since the use of medication event monitoring systems (MEMS^TM) caps prohibits liquid dosing. Exclusion Criteria for Parent or Caregiver None |
Country | Name | City | State |
---|---|---|---|
United States | National Institutes of Health Clinical Center | Bethesda | Maryland |
Lead Sponsor | Collaborator |
---|---|
National Cancer Institute (NCI) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Feasibility | Proportion of enrolled patients for which we are able to collect data from the MEMSTM system for two or more cycles of treatment (target = 75%) | Two cycles | |
Secondary | Pattern | Average percent adherence based on the MEMSTM data only for cycles 1-4, 5-8, 9-12 and 13-18 | Cycles 1-4, 5-8, 9-12 and 13-18 | |
Secondary | Patient Characteristics | Relationships between adherence (correlations, t-tests, etc.) and demographics, life events and barriers to adherence will be used to identify patient characteristics that may predispose to poor medication adherence | Two cycles |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT01362803 -
AZD6244 Hydrogen Sulfate for Children With Nervous System Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT00352599 -
Trial to Evaluate the Safety of Lovastatin in Individuals With Neurofibromatosis Type I (NF1)
|
Phase 1 | |
Completed |
NCT05005845 -
NFX-179 Topical Gel Treatment for Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF)
|
Phase 2 | |
Completed |
NCT00846430 -
Medical Treatment of "High-Risk" Neurofibromas
|
Phase 2 | |
Completed |
NCT03433183 -
SARC031: MEK Inhibitor Selumetinib (AZD6244) in Combination With the mTOR Inhibitor Sirolimus for Patients With Malignant Peripheral Nerve Sheath Tumors
|
Phase 2 | |
Recruiting |
NCT05331105 -
HL-085 in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas
|
Phase 2 | |
Completed |
NCT03310996 -
Non-invasive Stimulation in Neurofibromatosis Type 1
|
N/A | |
Recruiting |
NCT03406208 -
Resiliency Training for Adults With Neurofibromatosis Via Live Videoconferencing
|
N/A | |
Not yet recruiting |
NCT05849662 -
A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia
|
Phase 1/Phase 2 | |
Recruiting |
NCT04750928 -
Cyclin-Dependent Kinase (CDK)4/6 Inhibitor Abemaciclib for Neurofibromatosis Type I (NF1) Related Atypical Neurofibromas
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT06262113 -
A Decentralized Clinical Trial to Promote Evidence-Based Care for Underserved Patients With Neurofibromatosis 1
|
N/A | |
Active, not recruiting |
NCT04924608 -
Efficacy and Safety of Selumetinib in Adults With NF1 Who Have Symptomatic, Inoperable Plexiform Neurofibromas
|
Phase 3 | |
Recruiting |
NCT02544022 -
Development and Validation of Patient Reported Outcome (PRO) Measures for Individuals With Neurofibromatosis 1 (NF1) and Plexiform Neurofibromas (pNFs)
|
||
Not yet recruiting |
NCT06222203 -
Surveillance for Malignant Transformation of Neurofibromatosis Type 1 (NF1) Related Peripheral Nerve Sheath Tumors (PNST)
|
||
Recruiting |
NCT04941027 -
Evaluating Genetic Modifiers of Cutaneous Neurofibromas in Adults With Neurofibromatosis Type 1
|
||
Completed |
NCT02153931 -
Internet Support Group for Parents of a Child With Neurofibromatosis Type 1
|
||
Completed |
NCT05196854 -
Clinical Hypnosis and Home Blood Pressure Monitoring in Children With Neurofibromatosis Type 1
|
N/A | |
Active, not recruiting |
NCT01650142 -
Modifying Genes in Neurofibromatosis 1
|
N/A | |
Completed |
NCT05377008 -
Intervention Effectiveness on the Neurocognitive Functioning of Children and Adolescents With Neurofibromatosis Type 1
|
N/A | |
Completed |
NCT04879160 -
Systematically Assessing Changes in Plexiform Neurofibroma Related Disfigurement From Photographs of Subjects With Neurofibromatosis Type 1 on a Phase 2 Clinical Trial
|